World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
108
Citations
47850
World Ranking
969
National Ranking
41

Medicine

D-Index
109
Citations
52038
World Ranking
5709
National Ranking
316

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Nadia Harbeck is affiliated with Ludwig-Maximilians-Universität München in Germany. Their research spans primarily the field of Medicine with notable contributions to Biochemistry, Genetics, and Molecular Biology. Within these domains, the subfields of Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics, and Radiology, Nuclear Medicine, and Imaging have been prominent areas of study.

Their main topics of research focus on Breast Cancer Treatment Studies and Advanced Breast Cancer Therapies. Additional areas include HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, and Breast Lesions and Carcinomas.

Frequent co-authors collaborating with Nadia Harbeck include:

  • Rachel Wuerstlein
  • Oleg Gluz
  • Peter A. Fasching
  • Diana Lüftner
  • Rachel Würstlein

Their work has been published extensively in several key venues, including:

  • Annals of Oncology
  • Cancer Research
  • Journal of Clinical Oncology
  • Geburtshilfe und Frauenheilkunde
  • Breast Care

Notable papers with publication year and venue include:

  • Pembrolizumab for Early Triple-Negative Breast Cancer, 2020, New England Journal of Medicine
  • Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer, 2022, New England Journal of Medicine
  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial, 2020, The Lancet
  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5), 2020, Annals of Oncology
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, 2021, Annals of Oncology

Best Publications

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume

  • Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi

  • Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    David W. Miles;Arlene Chan;Luc Y. Dirix;Javier Cortés

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    Debu Tripathy;Seock Ah Im;Marco Colleoni;Fabio Franke

  • Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

    Seock-Ah Im;Yen-Shen Lu;Aditya Bardia;Nadia Harbeck

  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

    Elizabeth A Mittendorf;Hong Zhang;Carlos H Barrios;Shigehira Saji

  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

    F. Cardoso;A. Costa;L. Norton;E. Senkus

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • Triple-negative breast cancer—current status and future directions

    O. Gluz;C. Liedtke;N. Gottschalk;L. Pusztai

  • Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

    Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck

  • Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

    Michael Untch;Peter A. Fasching;Gottfried E. Konecny;Stephan Hasmüller

  • Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

    F. Janicke;A. Prechtl;C. Thomssen;N. Harbeck

  • Clinical impact of the plasminogen activation system in tumor invasion and metastasis : Prognostic relevance and target for therapy

    M Schmitt;N Harbeck;C Thomssen;O Wilhelm

  • Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).

    M.J. Duffy;N. Harbeck;M. Nap;R. Molina

  • Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.

    Hans-Joachim Stemmler;Manfred Schmitt;Amina Willems;Helga Bernhard

  • Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

    Fritz Jänicke;Manfred Schmitt;Lothar Pache;Kurt Ulm

  • Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Stephen R D Johnston;Nadia Harbeck;Roberto Hegg;Masakazu Toi

Frequent Co-Authors

Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Christoph Thomssen
Christoph Thomssen University of Göttingen
Manfred Schmitt
Manfred Schmitt Technical University of Munich
Hans Kreipe
Hans Kreipe Hannover Medical School
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Tanja Fehm
Tanja Fehm Heinrich Heine University Düsseldorf
Jens Huober
Jens Huober Kantonsspital St. Gallen
Hope S. Rugo
Hope S. Rugo University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine isn’t limited to becoming a physician. The healthcare field offers a variety of rewarding paths, many of which are accessible through flexible online education. For those considering advanced nursing roles, cheap online dnp programs can make it more affordable to earn a Doctor of Nursing Practice. Pharmacists in training can pursue their goals through online pharmacist programs, offering both convenience and recognized qualifications.

Beyond clinical roles, the healthcare industry also needs professionals to manage patient records and navigate insurance claims. Accredited rhit programs online prepare students for certification in health information management—a field that’s growing with the demand for digital records. Additionally, medical coding certification can open doors to in-demand administrative roles, often with the flexibility to work remotely.

These pathways offer alternative or complementary careers to medical school, each with unique benefits and educational requirements. Exploring these options can help you find a niche in healthcare that fits your interests, budget, and lifestyle.

Best Scientists Citing Nadia Harbeck

Trending Scientists

Recently Published Articles